Pre-randomization | Post-randomization | ||||||
---|---|---|---|---|---|---|---|
Screening/consent | Baseline (week: −1 to 0) | Intervention (weeks 1–8) | Immediate follow-up (week 9; 1 week post-M3) | Extended follow-up (week 18; 10 weeks post-M3) | |||
Session 1 | Sessions 2–7 | Session 8 | |||||
Screening form | X | ||||||
Informed consent-parent | X | ||||||
Assent child | Xa | ||||||
Clinician’s questionnaire | X | ||||||
Parent questionnaire | |||||||
QOLCE-55 | X | X | X | ||||
PCGRC | X | X | |||||
BASC-3 | X | X | X | ||||
BRIEF | X | X | X | ||||
SF-12 | X | X | X | ||||
CESD-R | X | X | X | ||||
GAD-7 | X | X | X | ||||
PSI-4-SF | X | X | X | ||||
Family APGAR | X | X | X | ||||
GASE | X | X | X | ||||
Demographics/clinical | X | X | X | ||||
Weekly Parent Questionnaire | X | X | X | ||||
Parent Pre-Post Assessment | X | X | |||||
Child Pre-Post Assessment | Xa | Xa | |||||
M3 Adherence checklist | X | X | X | ||||
Quality of Implementation | X | X | X | ||||
QOLCE-16 (if participant withdraws) | X | X |